Detailed View
RARE - Ultragenyx Pharmaceutical Inc.
Latest filing: 2026-06-30 | Reporting: gaap
Market Cap
1,470,945,920
Adj EBIT (TTM)
-528,173,000
Enterprise Value
1,352,945,920
Last Price
14.92
Earnings Yield
-39.04%
Return on Capital
-75.78%
Capital
697,000,000
1Y Price Chart
Last Price: -
1Y Change: -
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-06-30 | 10-Q | 2026 | 214,000,000 | -75,000,000 |
| 2026-03-31 | 10-Q | 2026 | 136,000,000 | -169,000,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | 207,279,000 | -113,283,000 |
| 2025-09-30 | 10-Q | 2025 | 159,933,000 | -170,890,000 |
| 2025-06-30 | 10-Q | 2025 | 166,496,000 | -107,888,000 |
| 2025-03-31 | 10-Q | 2025 | 139,292,000 | -142,939,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | 164,877,000 | -122,278,000 |
| 2024-09-30 | 10-Q | 2024 | 139,494,000 | -131,987,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.